Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10310995 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL13222901 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL12253802 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL10001262 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL14622977 | 0.87 | — | — | |
| SCHEMBL14624334 | 0.85 | — | — | |
| SCHEMBL18098021 | 0.85 | — | — | |
| SCHEMBL21123603 | 0.85 | — | — | |
| SCHEMBL22317546 | 0.85 | — | — | |
| SCHEMBL14537126 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801311-B2 | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides | GENZYME CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801311-B2 | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides | GYS1, PYGM, TNNC1 | FGF1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.